No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Administering bortezomib on a weekly basis VS twice weekly basis does not significantly affect progression-free survival (PFS) or overall survival (OS) in Vrd first-line therapy for multiple myeloma (bortezomib, lenalidomide, and dexamethasone)

byKathleen Lau

January 1, 2021

in StudyGraphics

Rosuvastatin therapy for people with HIV not associated with decreased biomarkers of inflammation and immune activation

RelatedReports

Lessons from real-world implementation of lung cancer screening

Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Oncology

Why Pfizer Is Looking East for Its Next Generation of Cancer Drugs

June 4, 2026

Pharma

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

June 3, 2026

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

2 Minute Medicine Rewind January 3, 2021

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

Cardiovascular medications may improve outcomes for patients with type 2 myocardial infarction

#VisualAbstract: Cabotegravir plus rilpivirine given every 8 weeks is non-inferior to every 4 weeks for maintenance of HIV-1 viral suppression

#VisualAbstract: Special Report: Vaccines in Development- Johnson & Johnson vaccine as another frontrunner

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports